In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
In recent transactions disclosed by Mersana Therapeutics, Inc. (NASDAQ:MRSN), Timothy B. Lowinger, the company's Senior Vice President and Chief Science & Technology Officer, sold shares of common ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...